---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-053532"
form_type: "8-K"
ticker: "ENTA"
cik: "0001177648"
company_name: "ENANTA PHARMACEUTICALS INC"
filed_at: "2024-05-06T23:59:59+00:00"
generated_at: "2026-06-02T21:47:12.092297+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Enanta Q2 net loss $31.2M; cash $300.3M; RSV data readouts expected in 2H 2024

## Summary
- Fiscal Q2 2024 revenue $17.1M (AbbVie HCV royalty); net loss $31.2M ($1.47 loss/share) vs $37.7M loss a year ago.
- Cash, equivalents, and marketable securities total $300.3M; expected runway through Q3 FY2027.
- Zelicapavir Phase 2 pediatric RSV data expected 2H 2024; EDP-323 challenge study data expected Q3 2024.
- KIT inhibitor development candidate for CSU targeted Q4 2024; second immunology program planned in 2024.
- Expense guidance updated: R&D $125M-$145M, G&A $50M-$60M due to immunology/RSV efforts and Pfizer patent lawsuit.

## SEC filing metadata
- accession: 0000950170-24-053532
- form_type: 8-K
- ticker: ENTA
- cik: 0001177648
- company_name: ENANTA PHARMACEUTICALS INC
- filed_at: 2024-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1177648/000095017024053532/0000950170-24-053532-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1177648/000095017024053532/enta-20240506.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-053532
- JSON: https://secwatch.observer/filing/0000950170-24-053532.json
- Plain text: https://secwatch.observer/filing/0000950170-24-053532.txt

## Key facts
- Earnings Releases
  ENANTA PHARMACEUTICALS INC reported fiscal quarter ended March 31, 2024 results: revenue $17.1 million, EPS a loss of $1.47 per diluted common share. Guidance reaffirmed.
  - Period: fiscal quarter ended March 31, 2024
  - Revenue: $17.1 million
  - EPS: a loss of $1.47 per diluted common share
  - Guidance: reaffirmed
  - Result: reported results
  source text: chronic diseases with a second program this year.” Fiscal Second Quarter Ended March 31, 2024 Financial Results Total revenue for the three months ended March 31, 2024 was $17.1 million and consisted of royalty revenue from worldwide net sales of AbbVie’s hepatitis C virus (HCV) regimen MAVYRET®/MAVIRET® (glecaprevir/pibrentasvir), compared to $17.8 million for
  evidence_url: https://www.sec.gov/Archives/edgar/data/1177648/000095017024053532/0000950170-24-053532-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.